I am compelled to rise today to comment once again on what I consider to be the troubling path that the Federal Government has taken with respect to this nation's high-tech industry. It has come to my attention that on Monday, the Federal Trade Commission will vote on whether to bring an antitrust action against Intel Corp. In November of last year I warned the Senate Judiciary Committee during a hearing on the Department of Justice's investigation of Microsoft of the slippery slope of more government regulation of, and intrustion into, America's high-technology sector. Monday's proposed vote makes clear to me that we are well into our slide. We are now witnessing a revolution in antitrust action in which it appears the federal government seeks to influence the very terms on which intellectual property is shared within an industry. We already have an entire field of laws that deal with this Mr. President. They are called ``patents,'' and to the extent that there are deficiencies in patent law, this Congress is attempting to address those concerns through legislation. We do not need the Federal Trade Commission's help in this endeavor. Let me make clear, I do believe in appropriate antitrust enforcement. In this industry, however, overzealous pursuit of alleged antitrust violations sends a chilling signal to one of this nation's most prized industries: Success is illegal, violators will be punished.
Editor's note · Context
Addressing concerns about government regulation of the high-tech industry and potential antitrust actions against Intel.
Share
More from Ralph Lee Abraham
Cyber-based intrusions and attacks on Federal systems and systems supporting our Nation's critical infrastructure, such as communications and financial services, are evolving and becoming more sophisticated.
I suspect they don't because it looks like to me that they have a plan to prop up the Marxist regime.
I remain very concerned that the VA is not yet appropriately prioritizing its workload and properly safeguarding taxpayer funds.
I'm a physician by trade, and I was taught very early in medical school when you review a scientific article to look at the author, whether there's bias or not, and look at the sample size.





